risk analysis, page-2

maca,

Personally I value fonda at 30c a share. That valuation may increase, as it sounds as though higher profits are coming.

There is then some value in the SCLC trail, the "Merck" lead trial and VAST (with the AstraZeneca funding). That lot is easily worth 10c a share.

So the HyI phase 3 is valued at about 18.5c by the market.

Given the chances of success - which I would put at 80% personally, and the potential upside - over ten fold the current 18.5c valuation, means that this has a fantastic risk/reward ratio imho.

Upside is further multiplied, as there are about eleven other HyACT drugs identified and ready to go into clinical trials!

There are no guarantees in the stock market. All we can do is invest wisely and hope for the best.

But imho investing in acl is investing wisely. Just spread your risk over a few others that are similarly "undervalued".

Best wishes